GSK3206641A
/ GSK
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 10, 2023
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older
(clinicaltrials.gov)
- P2 | N=833 | Completed | Sponsor: GlaxoSmithKline | Phase classification: P1/2 ➔ P2
Phase classification • Infectious Disease • Influenza • Respiratory Diseases
November 17, 2022
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older
(clinicaltrials.gov)
- P1/2 | N=840 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Influenza • Respiratory Diseases
1 to 2
Of
2
Go to page
1